PIVOT PHARMACEUTICALS

Executive Summary 2017

WOMEN'S HEALTH MARKET

The global market for women's health therapeutics was worth nearly $18.3 billion in 2012 and the market is expected to increase to nearly $22.5 billion in 2018, at a compound annual growth rate (CAGR) of 3.5%

ONCOLOGY MARKET

The worldwide sales for oncology products in 2012 were $68 billion and are estimated to increase to $114.4 billion in 2018, at a compound annual growth rate of 9.0%.

MANAGEMENT TEAM

Pravin Chaturvedi, PhD: Chief Executive Officer, Director

Ahmad Doroudian, PhD: Chief Business Officer, Director

Moira Ong, CA, CFA: Chief Financial Officer

NON-EXECUTIVE DIRECTORS

Patrick Frankham PhD, MBA: Director

Wolfgang Renz, MD, PhD: Director

SCIENTIFIC & ADVISORY BOARD MEMBERS

Steven Grossman, M.D., PhD:
Professor & Chair, Hematology/Oncology, VCU

Grannum Sant, M.D. F.R.C.S., F.A.C.S:
Former Chair, Urology, Tufts School of Medicine

Suzanne Mandala, PhD:
Former Exec. Director, Licensing, Merck.

ADVISORS

Davis Malm & D'Agostine P.C. www.davismalm.com

Alexander Holburn Beaudin + Lang www.ahbl.ca

Sadler, Gibb and Associates www.sadlergibb.com

MISSION

Pivot Pharmaceuticals is an emerging biotechnology company engaged in the development of novel therapeutics targeting unmet medical needs in women's health. It has a portfolio of drug candidates for the treatment of gynecological and breast oncology conditions such as metastatic endometrial and triple-negative breast cancers, some of which may also qualify as orphan diseases. The Company is also focused on the development of proprietary treatment options to other unmet diseases that may preferentially affect women's health. The Company plans to leverage appropriate regulatory strategies to accelerate time to market of its novel therapies, the first of which is planned for 2020.

VALUE PROPOSITION

The women's health and cancer markets are expected to grow to approximately $22.5 and $114 billion respectively by 2018. The Company will leverage novel technologies and drug candidates to enter this market place and develop and commercialize new products in these areas of high unmet need.

Specifically, the Company will bring new products to market to address women's health needs through a two-pronged approach of leveraging drug delivery technologies for improved delivery of drugs and it is also developing novel drugs for women's cancers, some of which qualify for orphan disease designation and provide longer market exclusivity. The use of novel drug delivery technologies will allow the Company to potentially advance existing drugs for treating disorders with a faster time-to-market, albeit with shorter market exclusivity.

The Company's novel anticancer drug portfolio provides new treatment options for resistant gynecological and triple-negative breast cancer needs, which have smaller numbers of patients and avail the opportunity of longer exclusivity period due to orphan disease nature of such patient populations.

Pivot has assembled a highly experienced management and advisory team that has clinical, commercial, product development and financial experience. Collectively the team has participated in the commercialization of more than 10 drugs representing a total market value in excess of several billion dollars.

CORPORATE INFORMATION

Symbol	PVOTF
Exchange	OTCQB
Share Price (Jan 4, 2017)	$0.14
Shares O/S	75,647,114
Shares O/S Fully Diluted	87,560,722

PIVOT COMPANY PIPELINE

Therapeutic Area	Indication	Product	IP Protection	Phase II a/b	Est. Registration / Licensing
Women's Cancers That Represent High Unmet Medical Needs Due To Genomic Mutations	Metastatic Endometrial Cancer	PVT-005	Composition of Matter & Methods Patents	2017-2018	2021
	Triple-Negative Breast Cancer	PVT-006	Composition of Matter & Methods Patents	2018-2019	2022

GLOBAL ONCOLOGY FORECAST



SOURCE: IMS Health MDAS, Dec 2014: IMS Health Market Prognosis, March 2015

THERAPEUTIC AREAS

Pivot has a portfolio of novel and proprietary anticancer drugs that target a novel pathway in DNA damage response for the treatment of metastatic endometrial, colorectal and triple-negative breast cancers that have mutations in the DNA repair pathways. Pivot has a strong patent estate with multiple issued patents and several patent applications that cover the composition of matter as well as methods of use for its anticancer drug portfolio. Pivot is also accessing novel drug delivery technologies and products through such technologies to buttress its portfolio of anticancer drugs, to provide short-term and long-term value drivers for the Company's growth through a diversified portfolio of novel therapeutics for improving women's health.

GYNECOLOGICAL & BREAST CANCER PROGRAMS

Pivot has a portfolio of novel anticancer drugs that have shown activity in resistant and refractory cancers affecting women. Specifically the Company will address cancers that are affected by changes such as loss of tumor suppression (p53), DNA mismatch repair and/or homologous recombination functions, that render cancers of the uterus, bladder, gastrointestinal tract, and triple-negative breast resistant to currently available therapies. Pivot's lead candidates are poised to enter Investigational New Drug (IND)-enabling studies to support filing for the initiation of human clinical trials in cancers such as metastatic endometrial and/or triple negative breast cancer. Pivot plans to initiate clinical testing of at least one lead clinical candidate within a 12-month period from initiation of its pre-IND studies.

DRUG DELIVERY TECHNOLOGIES FOR REPURPOSING DRUGS

Pivot is evaluating novel drug delivery systems to allow its development of treatments disorders that preferentially affect women's health such as lower urinary tract symptoms (LUTS), bladder pain and other conditions.

LEVERAGING REGULATORY PATHWAYS FOR FASTER TIME TO MARKET

Pivots oncology candidates will qualify for Orphan Drug Designation thus providing the company the opportunity to benefit from accelerated regulatory initiatives and longer term exclusivity for its approved drug(s). The drug delivery technologies initiatives will seek approval by leveraging the 505(b)(2) pathway outlined by the United States Food and Drug Administration (FDA), which allows the Company an accelerated time to market through the use of novel drug delivery technologies for existing drugs.